The startup has developed a site-specific protein conjugation platform that enables the creation of targeted protein-drug conjugates for cancer treatment. This technology addresses the inefficiencies of traditional protein conjugation methods by allowing healthcare providers to produce receptor proteins with precise chemical modifications, enhancing therapeutic efficacy.
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional protein conjugation methods often lack precision in controlling the conjugation site and the number of modifications, leading to inconsistent product quality and reduced therapeutic efficacy, particularly in the development of targeted protein-drug conjugates and conjugate vaccines. This inefficiency complicates the manufacturing process and limits the optimization of bioconjugates for stability, efficacy, and immunogenicity.
Solution
VALANX Biotech offers a site-specific protein conjugation platform, GoldenSite™, that leverages synthetic biology and genetic code expansion to provide precise control over the conjugation site and the number of conjugations on a protein of interest. By incorporating synthetic, bio-orthogonal chemical handles into proteins, the platform enables the creation of customized protein conjugates with optimized properties. This technology facilitates the development of next-generation bioconjugates, including antibody-drug conjugates (ADCs) and conjugate vaccines, with improved stability, efficacy, and therapeutic window. VALANX Biotech partners with pharmaceutical and biotech companies to streamline their conjugate development process, offering services from protein design to conjugate production and characterization.
Target Audience
The primary target audience includes pharmaceutical and biotech companies involved in the development of protein-drug conjugates, antibody-drug conjugates (ADCs), novel format conjugates, radioconjugates, and conjugate vaccines.
Features
- Proprietary GoldenSite™ technology for site-specific protein conjugation
- Genetic code expansion to incorporate synthetic amino acids at defined positions
- Precise control over conjugation site and stoichiometry
- Capability to conjugate a wide range of payloads, including drugs, dyes, and polymers
- Compatibility with both CHO and E. coli expression systems
- Streamlined process for generating and screening conjugate variants
- Expertise in optimizing bioconjugates for stability, efficacy, and immunogenicity
- Joint development of ClickCRM™, a ready-to-conjugate version of CRM197 for rapid conjugate vaccine development